Alnylam Pharmaceuticals prices public offering of common stock
21/01/2015 15:25
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced the pricing of an underwritten registered public offering of 4,736,842 shares of its common stock at a public offering price of USD 95 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 26, 2015, subject to the satisfaction of customary closing conditions. J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for the offering. Barclays Capital Inc., Piper Jaffray & Co., Cowen and Company, LLC, JMP Securities LLC, and Needham & Company, LLC are acting as co-managers for the offering. Alnylam has granted the underwriters a 30 day option to purchase up to 710,526 additional shares. Alnylam intends to use the net proceeds from this offering for general corporate purposes, focused on achieving its Alnylam 2020 profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of development, across its 3 Strategic Therapeutic Areas, or “STArs” – Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease – by the end of 2020. Alnylam expects these purposes to include research and development expenses, including clinical trial costs, and other potential expenses as detailed in the prospectus supplement.
21/01/2015 15:25
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced the pricing of an underwritten registered public offering of 4,736,842 shares of its common stock at a public offering price of USD 95 per share. All of the shares in the offering are to be sold by Alnylam. The offering is expected to close on or about January 26, 2015, subject to the satisfaction of customary closing conditions. J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for the offering. Barclays Capital Inc., Piper Jaffray & Co., Cowen and Company, LLC, JMP Securities LLC, and Needham & Company, LLC are acting as co-managers for the offering. Alnylam has granted the underwriters a 30 day option to purchase up to 710,526 additional shares. Alnylam intends to use the net proceeds from this offering for general corporate purposes, focused on achieving its Alnylam 2020 profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of development, across its 3 Strategic Therapeutic Areas, or “STArs” – Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease – by the end of 2020. Alnylam expects these purposes to include research and development expenses, including clinical trial costs, and other potential expenses as detailed in the prospectus supplement.
